Novogenia H1 FY26 operating loss narrows 4.1% to EUR 4.7 million; revenue falls 7% to EUR 25.7 million
Bitget2026/09/28 07:00- Novogenia revenue fell 7% to EUR 25.7 million in H1 2026.
- Operating loss narrowed 4.1% to EUR 4.7 million, after cost cuts; prior-year operating income had been lifted by one-off other income.
- Net result swung to a loss of EUR 2.1 million, versus profit a year earlier, after a weaker financial result.
- Cash and securities totaled EUR 39.8 million at June 30, 2026.
- CEO Daniel Wallerstorfer said core genetics and personalized health products improved; the group launched MGT Plus in the U.S. and began marketing Multi-Cancer Check.
Disclaimer: The content of this article solely reflects the author's opinion and does not represent the platform in any capacity. This article is not intended to serve as a reference for making investment decisions.
You may also like
CNN Enters Generative AI Partnership with Google
US Stock Market Movement | Nvidia-backed AI pharmaceutical company Iambic Therapeutics (IAM.US) debuts on Nasdaq, surging over 11% after opening
As of press time, the stock is up more than 11%, trading at $17.77.
US Stock Market Movement | 3D Printing Materials Supplier Amaero (AMRO.US) Debuts on US Stock Market, Trading Halt Triggered After Opening
Amaero, a manufacturer specializing in titanium and refractory metal powders for 3D printing in the defense and aerospace sectors, has gone public on the US stock market.
Crypto prices
More
